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To the Editor: 
An international collaboration has led to the development of a comprehensive tool [CLL-IPI 
international prognostic index for CLL] for the predicting of overall survival (OS) in chronic 
lymphocytic leukemia (CLL).
1
 CLL-IPI was based on data collected from 3500 CLL patients and was 
based on the following parameters: TP53 deletion and/or mutation, IGHV mutational status, 2-
microglobulin plasma levels, clinical stage, and age. CLL-IPI provides the means to stratify CLL 
patients in the daily clinical practice (Supplementary Table 1).
1
 Although validated for OS
2-4
 and time 
to first treatment (TTFT),
5
 the predictive value of CLL-IPI on progression-free survival (PFS) has 
until now only been demonstrated in a single study on patients treated with chlorambucil (CLB), as 
monotherapy, or in combination with obinutuzumab or rituximab, as a first-line approach (CLL11 
study),
6
 and presented as a poster at the annual meeting of the American Society of Hematology 
(ASH) in 2016. 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
The aim of the present study was to assess the predictive value of the CLL-IPI, determined at the time 
of first treatment, for PFS in a cohort of patients with CLL who underwent different front-line chemo-
immunotherapy treatment regimens: fludarabine-cyclophosphamide-rituximab (FCR), bendamustine-
rituximab (BR), pentostatin-cyclophosphamide-rituximab (PCR) or pentostatin-cyclophosphamide-
ofatumumab (PCO). 
This collaborative study included CLL patients from Italian, American, Israeli and German centers, 
who had received one of the above front-line regimens and for whom all five CLL-IPI markers had 
been evaluated at the time of first treatment. PFS was estimated for low-, intermediate-, high-, and 
very high-risk CLL-IPI scores. Additionally, risk-specific OS was also assessed. Methods included 
Kaplan-Meier curve, log-rank test, and Cox regression analyses. The prognostic accuracy of the 
predictive model was assessed by the Harrell C index (further details are in the Supplemental 
Appendix). 
A total of 845 CLL patients were included in this analysis and the majority were Binet stage B and C 
(77.9%). The median age was 63 years and 566 (67%) were male. Baseline clinical features are listed 
in Table 1; 402 cases received FCR, 252 BR, 142 PCR and 49 PCO between January 2003 and 
September 2016. After a median follow-up of 3.7 years from therapy start (range, 3 months to 15.7 
years), 157 patients had died and 402 experienced an event (death or progression). All clinicians 
applied IWCLL criteria to start therapy and to assess CLL progression. All patients were followed 
every 3 months.
7
 
First, we evaluated the capability of the CLL-IPI score to predict PFS. Due to missing data related to 
TP53 mutations, del17p was used as the sole marker of TP53 status. All selected markers had an 
independent prognostic impact on PFS (Supplementary Table 2). 
According to the CLL-IPI score, 183 patients (21.7%) were low-risk, 337 (39.9%) intermediate-risk, 
276 (32.7%) high-risk, and 49 (5.8%) very high-risk.  
PFS differed between the various CLL-IPI risk groups studied. The 3-year PFS probability was 82.6% 
(HR=1) for low-risk, 63.6% (HR=2.27; 95%CI 1.65–3.12, P<0.0001) for intermediate-risk, 53.9% 
(HR=2.87, 95%CI 2.08–3.97, P<0.0001) for high-risk, and 32.8% (HR=5.01, 95%CI 3.29–7.64, 
P<0.0001) for very high-risk patients (Figure 1A). The C-statistic for PFS was 0.61 (P<0.001). 
These results demonstrate the predictive power of CLL-IPI, determined at the time of first treatment, 
on PFS of CLL patients receiving different chemo-immunotherapy regimens as first-line treatment. 
Our data are in line with those of Goede et al
6
 who reported that groups with different PFS could be 
distinguished in a cohort of elderly unfit CLL patients receiving CLB or CLB plus an anti-CD20 
antibody as first-line treatment (CLL11 trial), based upon the CLL-IPI criteria. These findings are also 
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consistent with the observation that TP53 disruption, IGHV unmutated status or 2M levels, when 
considered as single parameters, are also associated with treatment outcomes after chemo-
immunotherapy.
8-14
 
Moreover, when the CLL-IPI was forced in a multivariate model together with the chemo-
immunotherapy regimen (FCR/PCR/PCO vs BR), both parameters remained significantly associated 
with PFS (CLL-IPI, HR 1.58; 95%CI 1.41-1.77, P<0.0001; FCR-PCR-PCO vs BR, HR 1.31; 95% CI 
1.02-1.67, P=0.033), showing that the CLL-IPI score allows of predicting the risk of progression 
regardless of the different chemo-immunotherapy approach.  
Stratification of patients according to the CLL-IPI criteria, evaluated at the time of first-line treatment, 
predicted significant differences also in terms of OS. Thus, low-risk patients had a 3-year OS 
probability of 96.6% (HR=1), intermediate-risk 92.8% (HR=3.73, 95%CI 1.84–7.57, P<0.0001), 
high-risk 81.4% (HR=7.35, 95%CI 3.66–14.77, P<0.0001), and very high-risk 64.7% (HR=17.3, 
95%CI 8.01–37.27, P<0.0001) (Figure 1B). The Harrell C-statistic was 0.69 (P<0.001) for predicting 
OS. 
Our data confirm the prognostic power of CLL-IPI when evaluated at the time of first-line therapy in 
patients treated with more aggressive chemo-immunotherapy regimens. These findings are in keeping 
and extend those reported in the original paper
1
 and by Goede et al.
6
 Overall, these results clearly 
indicate that CLL-IPI predicts PFS and OS independently of the type of chemo-immunotherapy 
administered. 
In conclusion, this is a validation study for CLL-IPI, assessed at the time of first-line treatment, in 
CLL patients who received a variety of chemo-immunotherapy approaches. The results confirm the 
ability of CLL-IPI to stratify patients’ outcomes in terms of both PFS and OS.  
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Figure Legends 
Figure 1. Progression-free survival (A) and overall survival (B) of the entire CLL cohort according to 
CLL-IPI score. 
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Table 1. Clinical features  
 
Features All cases 
(N=845) 
 No (%) 
Age, years  
≤ 506 (59.9) 
 339 (40.1) 
Sex  
Male  566 (67) 
Female 279 (33) 
Binet stage  
A 187 (22.1) 
B 504 (59.6) 
C 154 (18.2) 
2-M (mg/L)  
≤3.5  543 (64.3) 
>3.5 302 (55.7) 
IGHV mutational status   
mutated 329 (38.9) 
unmutated 516 (61.1) 
17p deletion   
no 791 (93.6) 
yes 54 (6.4) 
CLL-IPI score  
low 183 (21.7) 
intermediate 337 (39.9) 
high 276 (32.7) 
very high 49 (5.8) 
Therapy  
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FCR 402 (47.6) 
BR 252 (29.8) 
PCR 142 (16.8) 
PCO 49 (5.8) 
 
 
 
 
 
